Edward Kim, MD, PhD
Resident
University of Massachusetts Medical School
Dept of General Surgery


Websites
favorite icon LinkedIn




Pre-Doctoral Trainee (previously held)
Boston University School of Medicine, Graduate Medical Sciences
Pharmacology & Experimental Therapeutics


Pre-Doctoral Trainee (previously held)
Boston University School of Medicine, Graduate Medical Sciences
Program in Biomedical Neuroscience



2017 American Skin Association: Medical Student Grants Targeting Melanoma & Skin Cancer Research
2012 Boston University School of Medicine : MD/PhD Dean's Scholarship
2008 Howard Hughes Medical Institute : Summer Research Grant


p300 Mediates Melanoma Cell Growth and Survival Through the Transcriptional Regulation of MITF
01/01/2017 - 12/31/2017 (PI)
American Skin Association




Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, Venkatesh S, Cohen DL, Gonzalez EC, Ryu B, Cole PA, Alani RM. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Cancer Res. 2019 05 15; 79(10):2649-2661.View Related Profiles. PMID: 30910803
     
  2. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 01 04; 9(1):53.View Related Profiles. PMID: 29302039
     
  3. Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM. Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res. 2016 Aug; 26(4):321-8.View Related Profiles. PMID: 26881875; DOI: 10.1097/CMR.0000000000000190;
     
  4. Kim E, Wang Y, Kim SJ, Bornhorst M, Jecrois ES, Anthony TE, Wang C, Li YE, Guan JL, Murphy GG, Zhu Y. Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. Elife. 2014; 3. PMID: 25535838; PMCID: PMC4297949; DOI: 10.7554/eLife.05151;
     
  5. Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012 Aug 17; 150(4):816-30. PMID: 22901811; PMCID: PMC3427010; DOI: 10.1016/j.cell.2012.06.034;
     

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 5 publications over 5 distinct years, with a maximum of 1 publications in 2012 and 2014 and 2016 and 2018 and 2019

YearPublications
20121
20141
20161
20181
20191

Contact for Mentoring:

Kim's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_